Dosage Information for Ilaris: Form, Potency, Method of Administration, and Further Details
================================================================================
Ilaris, a brand-name drug, is a prescription medication approved by the Food and Drug Administration (FDA) to treat certain periodic fever conditions and Still's disease in adults and children. This medication is not available as a biosimilar at this time.
Ilaris is primarily used in individuals with familial Mediterranean fever (FMF), a condition more common in people of Mediterranean descent, as well as in those with hyperimmunoglobulin D syndrome/mevalonate kinase deficiency (HIDS/MKD), a genetic disorder. It is also approved for the treatment of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) and cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS).
The dosage of Ilaris is based on body weight and can vary depending on the specific condition and individual response to the medication. For Still's disease, the recommended dosage for children weighing 7.5 kg (16.5 lbs) or less is 2 mg/kg administered subcutaneously once every 4 weeks. If there is an inadequate response, the dose may be increased to 4 mg/kg every 4 weeks, with a maximum single dose of 300 mg.
For children weighing between 15 kg (about 33 lb) and 40 kg, the starting dose is 2 mg/kg every 4 weeks. Dose escalation to 4 mg/kg may be considered if the response is insufficient. The maximum dose per injection should not exceed 300 mg. For children weighing 40 kg (about 88 lb) or less, the recommended dosage for FMF, HIDS/MKD, and TRAPS is 2 mg/kg every 4 weeks, while children weighing more than 40 kg receive 150 mg every 4 weeks.
Ilaris is administered as a subcutaneous injection and is meant to be a long-term treatment. It is important that dosing is weight-based for pediatric patients and closely monitored by a physician.
If a dose of Ilaris is missed, it should be rescheduled as soon as possible. Ilaris is not prescribed based on age but rather on body weight and the condition being treated. It is not approved to treat anxiety.
Ilaris comes in one strength: 150 milligrams per milliliter (mg/mL). It is crucial to note that the dosing of Ilaris can be affected by other medical conditions. Therefore, it is essential to consult with a healthcare provider for personalised dosing recommendations.
In conclusion, Ilaris is a vital treatment option for certain periodic fever conditions and Still's disease in both adults and children. Dosing is based on body weight and closely monitored by a physician to ensure effective and safe treatment.
- In cases of chronic diseases like Still's disease and certain periodic fever conditions, medical professionals may recommend Pfizer's Ilaris for treatment, approved by the FDA for specific patients.
- In addition to treating familial Mediterranean fever and hyperimmunoglobulin D syndrome/mevalonate kinase deficiency, Ilaris is also utilized for disorders like tumor necrosis factor receptor-associated periodic syndrome and cryopyrin-associated periodic syndromes.
- It is essential for healthcare providers to monitor therapies and treatments like Ilaris, adjusting the dosage based on body weight and individual responses to ensure effective and safe health-and-wellness outcomes.
- Considering the complexities involved in managing chronic diseases and autoimmune disorders, consulting a healthcare provider for personalized dosing recommendations is highly advisable when using Ilaris or similar treatments.
